Tear film hyperosmolarity

Tear film hyperosmolarity refers to an abnormally high concentration of solutes (primarily salts) in the tear film covering the eye. It is not a discrete molecule or receptor but rather a *physiological state* that arises when there is either reduced aqueous tear production or increased evaporation of tears. This condition is central to the pathogenesis of dry eye disease and leads to damage of the ocular surface epithelium by triggering inflammatory cascades, apoptosis (cell death), loss of goblet cells, and disturbance in mucin expression[1][3][5]. The resulting instability further exacerbates hyperosmolarity in a vicious cycle. Tear film hyperosmolarity can be measured clinically as part of dry eye diagnosis; values above 300 mOsm/L or significant differences between eyes are considered abnormal[7]. It plays an important role in both preoperative assessment and postoperative management for procedures like cataract surgery because it can affect visual outcomes by destabilizing the ocular surface[2]. While not itself a therapeutic target like an enzyme or receptor, interventions such as **osmoprotectant-containing artificial tears** aim to mitigate its damaging effects on ocular tissues by restoring cellular homeostasis and reducing inflammation[1][5]. Because "tear film hyperosmolarity" describes a *state* rather than an individual molecular entity, it should not be classified as a canonical drug target.

Other names

Tear hyperosmolarityHyperosmolar tear filmIncreased tear osmolarity

Osmoprotectants stabilize cell volume and protein function to protect ocular surface cells from damage due to hyperosmolar stress[1]